Get started
Author

Matthew R. Kroll

ORCID: 0009-0003-3854-0942
Observed ORCID: 0009-0003-3854-0942
OpenAlex ID: A5111258181
Case report: Metastatic BRAF V600E–mutated adult Wilms’ tumor with robust response to BRAF/MEK inhibitor therapy
2024 · Matthew R. Kroll, Cherry Au, et al. · Frontiers in Oncology · 3
PDF
Phase I Clinical Trial of High Doses of Seleno-L-methionine in Combination with Axitinib in Patients with Previously Treated Metastatic Clear-cell Renal Cell Carcinoma
2025 · Yousef Zakharia, Ryan J. Reis, et al. · Clinical Cancer Research · 2
Anthracycline-containing versus anthracycline-free carboplatin-based regimens in early-stage triple-negative breast cancer: real-world outcomes
2026 · Matthew R. Kroll, Mary C. Schroeder, et al. · Breast Cancer Research and Treatment
PDF
Late recurrence of Wilms tumor after a 32−year disease−free interval: case report and literature review
2026 · Matthew R. Kroll, Rachaita Lakra, et al. · Frontiers in Oncology
Data from Phase I Clinical Trial of High Doses of Seleno-L-methionine in Combination with Axitinib in Patients with Previously Treated Metastatic Clear-cell Renal Cell Carcinoma
2025 · Yousef Zakharia, Ryan J. Reis, et al.
Supplementary Data1 from Phase I Clinical Trial of High Doses of Seleno-L-methionine in Combination with Axitinib in Patients with Previously Treated Metastatic Clear-cell Renal Cell Carcinoma
2025 · Yousef Zakharia, Ryan J. Reis, et al.
Supplementary Table 3 from Phase I Clinical Trial of High Doses of Seleno-L-methionine in Combination with Axitinib in Patients with Previously Treated Metastatic Clear-cell Renal Cell Carcinoma
2025 · Yousef Zakharia, Ryan J. Reis, et al.
Works count: 7
Citation count: 5
H-index: 2
I10-index:
Year
Topic
Type